Search Results - "Messing, M.J."

994O - Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

“…LEN is a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT. PEMBRO is an anti-PD-1 antibody. We report final results of a cohort of patients…”
Get full text

Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC) by Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Marin, M Romeo, Lorenzo, R Bratos, Brose, M.S., DiSimone, C., Messing, M.J., Stepan, D.E., Dutcus, C.E., Wu, J., Schmidt, E.V., Orlowski, R.J., Sachdev, P., Shumaker, R., Herraez, A Casado

Get full text